Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses

被引:25
作者
Chiang, Chen-Yi [1 ]
Huang, Ming-Hsi [1 ]
Hsieh, Chun-Hsiang [1 ]
Chen, Mei-Yu [1 ]
Liu, Hsueh-Hung [1 ]
Tsai, Jy-Ping [1 ]
Li, Yi-Shiuan [1 ]
Chang, Ching-Yun [1 ]
Liu, Shih-Jen [1 ,2 ]
Chong, Pele [1 ,2 ]
Leng, Chih-Hsiang [1 ,2 ]
Chen, Hsin-Wei [1 ,2 ]
机构
[1] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Taiwan
[2] China Med Univ, Grad Inst Immunol, Taichung, Taiwan
来源
PLOS NEGLECTED TROPICAL DISEASES | 2012年 / 6卷 / 05期
关键词
VIRUS TYPE-2; NEUTRALIZING ANTIBODIES; E-GLYCOPROTEIN; URIC-ACID; VACCINE; BINDING; IMMUNOGENICITY; INFECTIVITY; LIPOPROTEIN; CANDIDATES;
D O I
10.1371/journal.pntd.0001645
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The major weaknesses of subunit vaccines are their low immunogenicity and poor efficacy. Adjuvants can help to overcome some of these inherent defects with subunit vaccines. Here, we evaluated the efficacy of the newly developed water-in-oil-in-water multiphase emulsion system, termed PELC, in potentiating the protective capacity of dengue-1 envelope protein domain III. Unlike aluminum phosphate, dengue-1 envelope protein domain III formulated with PELC plus CpG oligodeoxynucleotides induced neutralizing antibodies against dengue-1 virus and increased the splenocyte secretion of IFN-gamma after in vitro re-stimulation. The induced antibodies contained both the IgG1 and IgG2a subclasses. A rapid anamnestic neutralizing antibody response against a live dengue virus challenge was elicited at week 26 after the first immunization. These results demonstrate that PELC plus CpG oligodeoxynucleotides broaden the dengue-1 envelope protein domain III-specific immune responses. PELC plus CpG oligodeoxynucleotides is a promising adjuvant for recombinant protein based vaccination against dengue virus.
引用
收藏
页数:10
相关论文
共 39 条
  • [1] Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates
    Bernard, Lidice
    Izquierdo, Alienys
    Alvarez, Mayling
    Rosario, Delfina
    Prado, Irina
    Lopez, Carlos
    Martinez, Rafael
    Castro, Jorge
    Santana, Ernidalys
    Hermida, Lisset
    Guillen, Gerardo
    Guzman, Maria G.
    [J]. ANTIVIRAL RESEARCH, 2008, 80 (02) : 194 - 199
  • [2] The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice
    Bernardo, Lidice
    Pavon, Alequis
    Hermida, Lisset
    Gil, Lazaro
    Valdes, Iris
    Cabezas, Sheila
    Linares, Ramon
    Alvarez, Mayling
    Silva, Ricardo
    Guillen, Gerardo
    Nagy, Eszter
    Schlick, Petra
    Guzman, Maria G.
    [J]. VACCINE, 2011, 29 (25) : 4256 - 4263
  • [3] A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice
    Block, Olivia K. T.
    Rodrigo, W. W. Shanaka I.
    Quinn, Matthew
    Jin, Xia
    Rose, Robert C.
    Schlesinger, Jacob J.
    [J]. VACCINE, 2010, 28 (51) : 8085 - 8094
  • [4] A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design
    Chen, Hsin-Wei
    Liu, Shih-Jen
    Liu, Hsueh-Hung
    Kwok, Yan
    Lin, Chang-Ling
    Lin, Li-Hsiu
    Chen, Mei-Yu
    Tsai, Jy-Ping
    Chang, Li-Sheng
    Chiu, Fang-Feng
    Lai, Li-wei
    Lian, Wei-Cheng
    Yang, Chiou-Ying
    Hsieh, Shih-Yang
    Chong, Pele
    Leng, Chih-Hsiang
    [J]. VACCINE, 2009, 27 (09) : 1400 - 1409
  • [5] Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate
    Chen, YP
    Maguire, T
    Hileman, RE
    Fromm, JR
    Esko, JD
    Linhardt, RJ
    Marks, RM
    [J]. NATURE MEDICINE, 1997, 3 (08) : 866 - 871
  • [6] A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses
    Chiang, Chen-Yi
    Liu, Shih-Jen
    Tsai, Jy-Ping
    Li, Yi-Shiuan
    Chen, Mei-Yu
    Liu, Hsueh-Hung
    Chong, Pele
    Leng, Chih-Hsiang
    Chen, Hsin-Wei
    [J]. PLOS ONE, 2011, 6 (08):
  • [7] Dengue vaccines: progress and challenges
    Coller, Beth-Ann G.
    Clements, David E.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2011, 23 (03) : 391 - 398
  • [8] Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells
    Crill, WD
    Roehrig, JT
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (16) : 7769 - 7773
  • [9] Dengue: a continuing global threat
    Guzman, Maria G.
    Halstead, Scott B.
    Artsob, Harvey
    Buchy, Philippe
    Jeremy Farrar
    Gubler, Duane J.
    Hunsperger, Elizabeth
    Kroeger, Axel
    Margolis, Harold S.
    Martinez, Eric
    Nathan, Michael B.
    Luis Pelegrino, Jose
    Cameron Simmons
    Yoksan, Sutee
    Peeling, Rosanna W.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2010, : S7 - S16
  • [10] Guzman MG, 2010, EXPERT REV VACCINES, V9, P137, DOI [10.1586/erv.09.139, 10.1586/ERV.09.139]